http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#Head http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#assertion http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#provenance http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#pubinfo http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#assertion http://purl.obolibrary.org/obo/DOID_7148 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_7148 http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB06674 http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#association http://www.w3.org/2000/01/rdf-schema#label simponi is a tumor necrosis factor tnf blocker indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis ra in combination with methotrexate 1 1 active psoriatic arthritis psa alone or in combination with methotrexate 1 2 active ankylosing spondylitis as 1 3 moderate to severe ulcerative colitis uc with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy 1 4 inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders simponi in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis simponi alone or in combination with methotrexate is indicated for the treatment of adult patients with active psoriatic arthritis simponi is indicated for the treatment of adult patients with active ankylosing spondylitis simponi is indicated in adult patients with moderately to severely active ulcerative colitis who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates oral corticosteroids azathioprine or 6 mercaptopurine for inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders see clinical studies 14 4 http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB06674 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#provenance http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#pubinfo http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#sig http://purl.org/nanopub/x/hasSignature AKTUt/2e3x0QG8TlJp+lA6J+n+M18JHh6DMOzd1UWENCw6EVJm5ZzpkncItdxqEUjCgdkkz5vwbnhHNI348YQR7RfMmmLxz0XOSVzOWmzt5q1sJxMWXRJHWIeRV8zLHuYrFUhWMhsWFFDd7awqVYKe+EO0dt8CL1Rgvnkmoli5w= http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s http://purl.org/dc/terms/created 2021-07-03T15:01:15.946+02:00 http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RALgu6FoqgLcLMQp2qqho20u1bNgVQ2_qKLT1ecRQ6W_s https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs